Clarithromycin should not be used in pregnant women except in clinical circumstances where no alternative therapy is appropriate. If pregnancy occurs while taking this drug, the patient should be apprised of the potential hazard to the fetus. Clarithromycin has demonstrated adverse effects of pregnancy outcome and/or embryo-fetal development in monkeys, rats, mice, and rabbits at doses that produced plasma levels 2 to 17 times. The serum levels achieved in humans treated at the maximum recommended human doses.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
